Meropenem Dosing for Acute Cholecystitis
For adults with acute cholecystitis and normal renal function, administer meropenem 1 gram intravenously every 8 hours as a 15-30 minute infusion. This is the standard dose for complicated intra-abdominal infections, which includes acute cholecystitis 1, 2.
Standard Dosing Algorithm
Adults with Normal Renal Function (CrCl >50 mL/min)
- Dose: 1 gram IV every 8 hours
- Infusion time: 15-30 minutes (or 3-5 minutes as bolus injection for 1 gram doses)
- Duration: Discontinue within 24 hours after cholecystectomy unless infection extends beyond the gallbladder wall 1
Adults with Renal Impairment
Dose adjustments are critical when creatinine clearance falls below 50 mL/min 2:
- CrCl 26-50 mL/min: 1 gram every 12 hours
- CrCl 10-25 mL/min: 500 mg every 12 hours
- CrCl <10 mL/min: 500 mg every 24 hours
For patients on continuous renal replacement therapy (CRRT), clearance increases substantially—approximately 2.1 times compared to non-CRRT patients with renal impairment 3. In CRRT patients, use 500 mg every 6 hours as a 3-hour infusion 3.
Pediatric Dosing (≥3 months)
For pediatric patients with complicated intra-abdominal infections 1, 2:
- Dose: 20 mg/kg every 8 hours (maximum 1 gram per dose)
- Infusion time: 15-30 minutes
For infants <3 months with complicated intra-abdominal infections, dosing depends on gestational and postnatal age 2:
- <32 weeks GA, PNA <2 weeks: 20 mg/kg every 12 hours
- <32 weeks GA, PNA ≥2 weeks: 20 mg/kg every 8 hours
- ≥32 weeks GA, PNA <2 weeks: 20 mg/kg every 8 hours
- ≥32 weeks GA, PNA ≥2 weeks: 30 mg/kg every 8 hours
Context for Acute Cholecystitis
The 2010 IDSA guidelines specifically address biliary infections 1. For community-acquired acute cholecystitis of mild-to-moderate severity, first-line agents are actually cefazolin, cefuroxime, or ceftriaxone—not carbapenems 1. Meropenem is reserved for severe acute cholecystitis (with severe physiologic disturbance, advanced age, or immunocompromised state) or healthcare-associated biliary infections 1.
For severe community-acquired or healthcare-associated biliary infections, meropenem is appropriate alongside other broad-spectrum options like imipenem-cilastatin, doripenem, or piperacillin-tazobactam 1. The 2021 WSES guidelines on bile duct injury similarly recommend broad-spectrum antibiotics including meropenem for patients with biliary fistula, biloma, or bile peritonitis 4.
Critical Considerations
Anaerobic coverage is not required for acute cholecystitis unless a biliary-enteric anastomosis is present 1. Meropenem provides adequate anaerobic coverage inherently, so additional metronidazole is unnecessary.
Enterococcal coverage is not routinely needed for community-acquired biliary infections 1. However, for healthcare-associated infections or immunosuppressed patients (particularly liver transplant recipients), consider adding vancomycin for enterococcal coverage 1.
Extended infusion strategies (3-hour infusions) may improve pharmacodynamic target attainment, particularly in critically ill patients or those with augmented renal clearance 5, 6, 7. For pathogens with MIC ≥4 mg/L, 3-hour infusions every 6 hours significantly increase the probability of achieving 100% fT>MIC 8.
Therapeutic drug monitoring should be considered in critically ill patients, those with renal dysfunction, or when treating resistant organisms 5, 3. Target trough concentrations depend on pathogen MIC, but maintaining free drug concentrations above 4× MIC throughout the dosing interval optimizes outcomes 9.
Common Pitfalls
The most significant error is using meropenem as first-line therapy for mild-to-moderate community-acquired acute cholecystitis when narrower-spectrum cephalosporins are appropriate 1, 10. A recent study found only 45% adherence to IDSA guidelines, with overuse of broad-spectrum agents 10. Reserve meropenem for severe disease, healthcare-associated infections, or documented resistant organisms.
Failure to adjust for renal function is another critical error. Even mild renal impairment (CrCl 26-50 mL/min) requires dose reduction to every 12 hours 2. Conversely, patients with augmented renal clearance may require higher doses (up to 6 g/day by continuous infusion) to achieve adequate exposure 6.
Prolonging therapy beyond source control is unnecessary. Once cholecystectomy is performed and infection is confined to the gallbladder wall, discontinue antibiotics within 24 hours 1.